Skip to content

Ketamine for depression: all studies

Page 75 of 154: studies 741 to 750 of 1,534, newest first. Back to the ketamine for depression overview

Research

The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol.

Alpha psychiatry August 1, 2024 Francesco Bartoli, Daniele Cavaleri, Ilaria Riboldi et al. 4 citations

Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow...

The N-methyl-d-aspartate receptor hypothesis of ketamine's antidepressant action: evidence and controversies.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences July 29, 2024 Yihao Jiang, Yiyan Dong, Hailan Hu

Substantial clinical evidence has unravelled the superior antidepressant efficacy of ketamine: in comparison to traditional antidepressants targeting the monoamine systems, ketamine, as an N-methyl-d-aspartate receptor (NMDAR) antagonist, acts much faster and more potently. Surrounding the antidepressant mechanisms of ketamine, there is ample evidence supporting an NMDAR-antagonism-based...

DOI: 10.1098/rstb.2023.0225 (opens in new tab) Full text (opens in new tab) Nmdar hypothesis Nmdar inhibitors Antidepressant efficacy Depression treatment +4

Ketamine in fibromyalgia: a systematic review.

Advances in rheumatology (London, England) July 29, 2024 Jozélio Freire de Carvalho, Eduardo Pondé de Sena 8 citations

Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients. We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021....

DOI: 10.1186/s42358-024-00393-9 (opens in new tab) Full text (opens in new tab) Depression Anesthetics Ketamine therapy Chronic pain treatment +3

Basic aspects of ketamine therapy for treatment-resistant depression - a review paper

Quality in Sport July 28, 2024 Weronika Szafrańska, Dominika Poborowska, Tomasz Gańko et al.

Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first line of pharmacological treatment is usually monoamine reuptake inhibitors. Up to 60% of cases, may be drug-resistant patients, prompting researchers to research substances other than conventional. 1 The purpose of this article was to review recent...

A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

BMC Psychiatry July 18, 2024 Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. 11 citations

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...

DOI: 10.1186/s12888-024-05951-5 (opens in new tab) Full text (opens in new tab) Response Tolerability Depression treatment Ketamine therapy +3

Long-term follow-up of participants in ketamine clinical trials for mood disorders.

Journal of Affective Disorders July 15, 2024 Kelly T Hurst, Abigail Vogeley, Deanna K Greenstein et al. 8 citations

Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a unique opportunity to assess long-term outcomes. This analysis evaluated the relationship between participating in a ketamine clinical trial and subsequent ketamine/esketamine use after leaving the research setting. Participants seen within the NIMH...

DOI: 10.1016/j.jad.2024.04.062 (opens in new tab) Full text (opens in new tab) Esketamine Clinical trials Clinical-trials Depression-treatment +3

Esketamine in depression: putative biomarkers from clinical research.

European Archives of Psychiatry and Clinical Neuroscience July 13, 2024 Jenessa N Johnston, Carlos A. Zarate, Mark D Kvarta 18 citations

The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant depression (TRD) are significant advances in the development of novel neuropsychiatric therapeutics. Esketamine is now recognized as a powerful tool for addressing persistent symptoms of TRD compared to traditional oral...

DOI: 10.1007/s00406-024-01865-1 (opens in new tab) Full text (opens in new tab) Spravato Mechanism of action Suicide Treatment-resistant depression trd +6

Electroencephalography and Magnetoencephalography Signatures of Ketamine Treatment in Depression: A Literature Review

Undergraduate Research in Natural and Clinical Science and Technology Journal July 11, 2024 Eva M. Geoghegan

Introduction: Ketamine has been shown to have rapid antidepressant effects. In addition, the use of EEG in depression offers a new approach to diagnose patients. It is necessary to understand locational-based EEG and MEG changes following ketamine in patients with depression to establish a potential biomarker panel. This study sought to identify consistent changes in band power as well as to...

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions

Journal of Anesthesia and Translational Medicine July 11, 2024 Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al. 32 citations

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...

The effectiveness of ketamine in medication of treatment-resistant depression - review

Quality in Sport July 10, 2024 Patrycja Brzozowska, Klaudia Bulska, Konrad Sławek et al.

In spite of the variety of antidepressant drugs available for treating depressive disorder, treatment resistant depression (TRD) is still prevalent among the population. Despite being used mainly in anesthesia, and mostly phased out by more modern anesthetics, ketamine shows potential when it comes to depressive disorder treatment. We've set out to investigate the the relevant body of work to...